For investors evaluating emerging medical technology companies, the competitive advantages behind a product can be as important as financial results. That was the focus of a recent Medsider interview with Dr. Sudhir Srivastava, founder, chairman and CEO of SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies, who discussed the company’s strategy to broaden access to robotic surgery through lower-cost technology, physician training and remote surgical capabilities.
Rather than concentrating solely on competing with existing robotic surgery platforms, Dr. Srivastava described SS Innovations’ objective as expanding access to hospitals and patients that have historically been unable to adopt robotic surgery because of equipment costs and operating expenses. The company’s SSi Mantra system was designed to reduce the cost of robotic surgery while supporting multiple specialties, including cardiac surgery. Affordability and accessibility remain the company’s core priorities as it expands its surgical robotics platform globally, with artificial intelligence, automation, and new robotic platforms central to the company’s long-term product roadmap.
Telesurgery and teleproctoring are becoming important differentiators, allowing expert surgeons to support complex procedures remotely. The company has installed more than 200 robotic systems and completed more than 11,700 robotic procedures, including over 170 telesurgeries. SS Innovations is pursuing FDA and European regulatory approvals while expanding into additional international markets.
According to the company, the SSi Mantra system is designed to address the cost barrier that has limited robotic surgery adoption. By offering a more affordable platform, SS Innovations aims to bring robotic surgery to a broader range of hospitals and patients worldwide. The company’s focus on telesurgery also enables remote training and support, which can accelerate adoption in regions lacking local experts.
As SS Innovations continues to scale, its progress in regulatory approvals and commercial deployment will be key metrics for investors. The company is actively working to secure approvals from the U.S. Food and Drug Administration and European regulatory bodies, which would open large markets. For more information on the latest news and updates relating to SSII, visit the company’s newsroom at https://ibn.fm/SSII.
